Becton, Dickinson and Company

Becton, Dickinson and Company delivered an all-around beat in the most recent quarterly result. The company outperformed its expectations with 8.7% base sales growth and double-digit currency-neutral earnings growth. In the quarter, the PowerMe Midline Catheter in the BD Medical section was introduced in China, and by the beginning of March, the first patient had already received it. In their Life Sciences division, they are enthusiastic about the performance of the BD COR platform, which is enabling the team to enter the high-throughput, high-growth molecular diagnostics sector. In Q2, BD debuted its Highlander 014 PTA balloon for its BDI market. Additionally, the company launched a revolutionary new cell sorting instrument that utilizes two ground-breaking technologies to reveal previously hidden cellular details in conventional flow cytometry experiments. We give Becton, Dickinson and Company a ‘Hold’ rating with a revised target price.